Introduction
============

Spinal cord injury (SCI) is recognized as a catastrophic threat to human health, with a gradually increasing morbidity rate worldwide ([@b1-ijmm-41-06-3267],[@b2-ijmm-41-06-3267]). It is known that hemi-sectioned SCI (hSCI) can lead to spastic paralysis on the injured side, as well as flaccid paralysis on the other side, and its injury degree lies between that of contusion injury and transection injury. hSCI results in marked motor impairments that harm the daily quality of life ([@b3-ijmm-41-06-3267]), however, stem cell therapy could offer an effective treatment solution ([@b4-ijmm-41-06-3267]-[@b7-ijmm-41-06-3267]).

It is known that stem cells are a type of multi-potent cell with the ability to replicate (self-renewal). Under certain conditions, they can differentiate into various functional cells ([@b8-ijmm-41-06-3267],[@b9-ijmm-41-06-3267]). Neural stem cells (NSCs), an important type of stem cell, possess the potential for giving rise to cells that are identical to themselves (self-renewal) ([@b10-ijmm-41-06-3267]) and producing neurons, astrocytes and oligodendrocytes (pluripotency) ([@b11-ijmm-41-06-3267]). NSC transplantation may shed new light on the practical study of central nervous system injury ([@b4-ijmm-41-06-3267],[@b12-ijmm-41-06-3267]), and NSCs could serve as the ideal source of transplanted cells. Moreover, NSCs are able to restore defective nerve tissues by self-proliferation and differentiation ([@b13-ijmm-41-06-3267]), and secrete a variety of neurotrophic factors (NTFs), including ciliary NTF (CNTF), transforming growth factor-β1 (TGF-β1), glial cell line-derived NTF (GDNF), nerve growth factor (NGF), brain-derived NTF (BDNF) and insulin-like growth factor (IGF) ([@b14-ijmm-41-06-3267]). As grafted cells, the expression of these NTFs from NSCs may support the survival and proliferation of host neural cells by improving the microenvironment, promoting expression of regeneration-related genes and accelerating local spinal cord restoration ([@b15-ijmm-41-06-3267]-[@b17-ijmm-41-06-3267]). However, the extensive evidence concerning the recovery of motor function following NSC transplantation after SCI has mainly been reported in rodents ([@b18-ijmm-41-06-3267],[@b19-ijmm-41-06-3267]). Primates are so scarce and valuable, while rodents including rats and mice are greatly different from primates. Therefore, tree shrews are the best choice for the source of NSCs. Crab-eating monkeys have such disadvantages as a high cost, lower availability and difficulty in breeding. However, for human embryos, ethical issues exist ([@b20-ijmm-41-06-3267]-[@b23-ijmm-41-06-3267]). Thus, a novel animal model for NSC transplantation is required. With the successful isolation of NSCs in the adult rodent, the study of NSCs in tree shrews (TS), a non-human primate, is becoming a focus, as they present with more advanced development than rats, have a lower economic cost and are a more convenient resource than monkeys, and the closest relative to primates ([@b24-ijmm-41-06-3267],[@b25-ijmm-41-06-3267]).

Furthermore, TSs have successfully been turned into an animal model for the study of hepatitis B virus infection ([@b26-ijmm-41-06-3267]-[@b28-ijmm-41-06-3267]), myopia ([@b29-ijmm-41-06-3267]), depression ([@b30-ijmm-41-06-3267]) and bacterial infection ([@b31-ijmm-41-06-3267]). However, TSs in the hSCI model and TS NSC transplantation into the hSC have not previously been studied, and the molecular factors of TS NSC grafts remain to be decided. Therefore, in the present study, a TS hSCI model was established to investigate the effect of TS NSC transplantation on the motor function improvement in the acute and chronic stages, and the possible mechanisms involved in associated features such as proliferation, differentiation and NTF secretion were examined.

Materials and methods
=====================

Animals and ethics statement
----------------------------

The present study used 3 female TSs who were 20 days pregnant and 50 healthy adult female TSs, weighing 120±20 g, 6 months old, which were obtained from the Experimental Animal Center of Kunming Medical University (Kunming, Yunnan, China) and were housed in the Laboratory Animal Center of Sichuan University (Chengdu, Sichuan, China). Animal experimental protocols were approved and performed according to the guidelines of the Institutional Medical Experimental Animal Care Committee of Sichuan University, West China Hospital (Sichuan, China). Guidelines for Laboratory Animal Care and Safety from the Unites States National Institutes of Health (Bethesda, MD, USA) were also followed. Animals were raised in separated cages in a room with a temperature of 20±5°C, 40-60% humidity and using a 12:12-h light/dark cycle, with free access to pellet chow and water. The breeding cages were plastic, equipped with stainless steel cup with lid cover and a plastic water jar. Following hSCI experiments, body temperatures were maintained, and the bladders of the TSs were manually massaged three times daily to enhance their function.

Isolation of NSCs
-----------------

The pregnant TSs were euthanized with a mixture of 70% CO~2~ and 30% O~2~. Next, the embryonic TSs were harvested under sterile conditions and immersed in an incubator filled with D-Hank\'s solution (Thermo Fisher Scientific, Inc., Waltham, MA, USA). Under an anatomical microscope, the hippocampi of the embryonic TSs were harvested and placed in a centrifuge tube for later use. To isolate the NSCs, the hippocampi were sectioned into small pieces and digested with 0.25% trypsin (1:250; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) for 20 min, and then Dulbecco\'s modified Eagle\'s medium (DMEM)/F12 (1:1; Gibco; Thermo Fisher Scientific, Inc.) containing serum was added to stop the digestion. Following centrifugation at 560 × g (4°C) for 5 min, the supernatant was discarded, and 100 ml DMEM/F12 medium (1:1) was added, with addition of 2 ml 1% B27 (both Gibco; Thermo Fisher Scientific, Inc.), 2 mmol/l glutamine, 2 *μ*g basic fibroblast growth factor (basic FGF; PeproTech, Inc., Rocky Hill, NJ, USA), 1% N2 (Gibco; Thermo Fisher Scientific, Inc.), 10,000 U/l penicillin and 10 mg/l streptomycin. Next, the cell suspension was harvested and the cells were inoculated onto culture plates or bottles at a density of 5×10^5^/ml, then kept in an incubator containing 5% CO~2~ at 37°C. The culture medium was half replaced every other day.

NSC passaging
-------------

At 7 days post-culture, when the cells had grown to near confluency, they were passaged two to four times. Briefly, following centrifugation at 560 × g (4°C) for 5 min in a 15-ml centrifuge tube, the supernatant was discarded. The cell suspension was re-suspended into DMEM/F12 containing FGF (20 ng/ml) and epidermal growth factor (20 ng/ml). The cellular density was adjusted to 1.5-2.5×10^6^/ml and inoculated into the culture bottles (25 ml in volume). Subsequent to lightly swaying the culture bottle for well distribution, the cultured NSCs were incubated in an 37°C incubator.

Cultured NSCs at passage two (P2) were collected for later use: A small quantity of NSCs was used for cell identification, some of them were used to identify their differentiation ability, some were used to detect their secretory functions and a large number were marked by Hoechst 33342 for transplantation in the hSC.

Morphological observation
-------------------------

During the primary and secondary culture of cells derived from the hippocampus of the TSs, an inverted phase-contrast microscope (Leica Microsystems GmbH, Wetzlar, Germany) was employed to observe and record the morphology and growth situation, including size, diameter and shape of NSCs at day 1-7 of P0, P1 and P2, respectively. The formation of neurospheres was also observed.

Experimental groups
-------------------

A total of 50 female TSs were randomly divided into the sham group, the acute hSCI with medium (MEM) (acute control) group, the acute hSCI with NSC implantation (acute) group, the chronic hSCI with NSC implantation (chronic) group and the chronic hSCI with MEM (chronic) group, with 10 TSs in each group ([Table I](#tI-ijmm-41-06-3267){ref-type="table"}). TSs in the acute or acute control groups underwent hSCI and were treated with NSC suspension or MEM immediately after injury. TSs in the chronic or chronic control groups were subjected to hSCI and received the NSC suspension or MEM at day 9 post-injury. TSs in the sham group underwent neither hSCI nor transplant injections ([Table I](#tI-ijmm-41-06-3267){ref-type="table"}).

hSCI model
----------

All TSs were anesthetized intraperitoneally with by 2% sodium pentobarbital (30 mg/kg) and placed in the prone position. A midline skin incision was made at the thoracic area (T8-T12) and then the paravertebral muscles and supraspinal ligaments were separated. TSs then underwent a T10 laminectomy and received an hSCI. The surgical wounds were closed with 3-0 silk sutures, and the TSs were injected with normal saline (0.9%; 5 ml) and received cefotaxime sodium (2.5%; 0.5 ml) for 7 days. The bladders of the TSs were manually compressed three times a day until the recovery of the micturition reflex.

NSC labeling and transplantation
--------------------------------

Hoechst 33342, a nuclear dye was used for NSC transplantation labeling. To label implanted cells, 3 mg/ml Hoechst (Sigma-Aldrich; Merck KGaA) was added to the medium at 72 h prior to transplantation. For tracing cells after transplantation, NSCs labeled with Hoechst 33342 could be observed under a fluorescence microscope (Leica Microsystems GmbH). For transplantation, cells were isolated by treatment with 0.25% trypsin (Sigma-Aldrich; Merck KGaA) and 0.5 mm EDTA (Sigma-Aldrich; Merck KGaA) at room temperature for 10 min. The digestion was stopped by adding 1 ml fetal bovine serum. The cells were then washed five times with phosphate-buffered saline (PBS). Nucleated NSCs were counted using a cytometer to guarantee sufficient NSC numbers for transplantation. In total, \~6 *μ*l cell suspension (1×10^7^/ml) or equivalent normal MEM was slowly transplanted into the spinal cord around the injury site, and at day 9 post-injury, respectively. Following transplantation, the T10 spinous process was tightened with 1-0 silk suture to prevent kyphosis and to obtain contact between the graft and spinal cord stumps. Muscle and skin were sutured layer to layer, and the TSs were placed in warm cages overnight. Food and water were provided *ad libitum*. Manual bladder expression was performed twice a day until recovery of the bladder reflex.

Behavior evaluation
-------------------

To compare the effect of NSC transplantation on the injured spinal cord, locomotor functional recovery was examined in the TSs at days 1-16 following hSCI, as determined by the Basso-Beattie-Bresnahan motor score (BBB score), which was graded from 0 points (absence of any hind limb movement) to 21 points (normal mobility) ([@b32-ijmm-41-06-3267]). Subjects were acclimated to the open enclosure (99 cm in diameter, 23 cm deep) for 3 days prior to detection for 5 min/day, as TSs often remain motionless when introduced to a new apparatus. Each subject was then observed for 4 min. All measurements were conducted in a double-blind manner. The mean score was determined from 3 individual researchers.

Immunohistochemistry
--------------------

Immunohistochemical staining was performed to confirm the cultured NSCs and their differentiation ability, as well as to detect the expression of the trophic factors *in vitro*. Meanwhile, the survival, migration and differentiation of NSCs *in vivo* after transplantation were also evaluated.

For *in vitro* detection, the cell suspension of P2 was moved to the 6-well plates and dropped onto sterile cover slips. The 6-well plates containing the NSCs were incubated at 37°C and the purified NSCs were fixed with 4% paraformaldehyde for 20 min. For *in vivo* detection, at 16 days post-injury, the TSs were anesthetized with 2% pentobarbital sodium 30 mg/kg \[intraperitoneal (i.p.)\] and underwent transcardiac perfusion with heparinized 0.9% saline, followed by 4% formaldehyde in 0.1 ml ice-cold phosphate buffer (pH 7.4; Shanghai Haoran Biotechnology Co., Ltd., Shanghai, China). Next, the samples collected from 20-mm long spinal cord segments containing the injury and injection sites, were post-fixed for 5 h at 4°C. Once the spinal cords from the different groups had been embedded in the same paraffin, respectively, the blocks were cut into 4-*μ*m sections for later use. After routine de-paraf-finization and rehydration, immunohistochemistry analysis was performed on the sections of spinal cord tissue.

Rinsed with 0.01 M PBS, the glass slides of the cultured NSCs and spinal cord sections were incubated with 5% goat serum for 30 min at 37°C to quench non-specific binding. Next, they were incubated overnight at 4°C with primary antibodies of nestin (a marker of NSCs), neuron-specific nuclear protein (NeuN; a marker of neurons), glial fibrillary acidic protein (GFAP; marker of astrocytes) and trophic factors (CNTF, TGF-β1, GDNF, NGF, BDNF and IGF) ([Table II](#tII-ijmm-41-06-3267){ref-type="table"}). As for the control group, the primary antibody was substituted with 0.01 M PBS. Thereafter, the glass slides and tissue sections were washed with 0.01 M PBS three times, each for 2 min. The slides and sections were then incubated with secondary antibodies ([Table II](#tII-ijmm-41-06-3267){ref-type="table"}) at 37°C for 30 min. Sections were observed under an immunofluorescence microscope (Leica Microsystems GmbH). Furthermore, 4′,6-diamidino-2-phenylindole (DAPI) was used to counterstain the nuclei. Finally, in order to determine the positive number stained *in vitro*, cells from five fields in each well were collected, each detection *in vitro* was prepared for 6 plates (6-pore plate) of cells and each pore was put into one sterile cover slip.

For detection *in vivo*, five fields for each section and five sections for each detection were selected randomly. All the detections were evaluated by 3 investigators blinded to the experimental information using Image-Pro Plus 6.0 software (Media Cybernetics, Silver Spring, MD, USA), and then the mean rates of positive cells for each detection were calculated.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)
----------------------------------------------------------------------

At 16 days post-injury, the spinal cord caudal to the injury site (20-mm long containing the injury and injection sites) was harvested after 2% pentobarbital sodium (30 mg/kg; i.p.) anesthesia and placed into a 1.5-ml Eppendorf tube without RNase, then stored at −80°C. Afterwards, the mRNA of the NTFs, including NGF, CNTF, BDNF, GDNF, TGF-β1 and IGF, were detected by RT-qPCR. Briefly, total RNA from the spinal cord tissues was isolated using TRIzol reagent (SuperfecTRI™) according to the manufacturer\'s protocol (Invitrogen; Thermo Fisher Scientific, Inc.), and reverse transcribed to cDNA with the RevertAid™ First Strand cDNA synthesis kit (Thermo Fisher Scientific, Inc.). Single-stranded cDNAs were synthesized by incubating template RNA (2.5 *μ*g) with oligo(dT)~18~ primer (1 *μ*l) and nuclease-free water (to 12 *μ*l) at 65°C for 5 min in a volume of 12 *μ*l, followed by mixing RevertAid M-MuLV Reverse Transcriptase (200 *μ*/μl, 1 *μ*l) with 5X reaction buffer (4 *μ*l), RiboLock RNase Inhibitor (20 *μ*/*μ*l, 1 *μ*l) and 10 mM dNTP Mix (2 *μ*l) with incubation for 60 min at 42°C in a final volume of 20 *μ*l. The reaction was terminated by heating to 70°C for 5 min. PCR was performed using s T100™ Thermal Cycler (Bio-Rad Laboratories, Inc., Hercules, CA, USA) to validate the level of NTFs; 5 *μ*l of 5-fold diluted template cDNA was added in each system, with a final volume of 25 *μ*l. Subsequently, RT-qPCR of cDNA was performed using the forward and reverse primer sequences as shown in [Table III](#tIII-ijmm-41-06-3267){ref-type="table"}. PCR amplification was performed as follows: i) Initial denaturation (1 cycle, 95°C for 3 min); ii) denaturation (40 cycles, 95°C for 15 sec); and iii) amplification (40 cycles, 53°C for 30 sec and 60°C for 40 sec). The PCR products were verified by 1% agarose gel electrophoresis, visualized by GoldView (Wolsen) staining (Xi\'an Wolsen Bio-Technology Co., Ltd, Xi\'an, China). The gels were scanned using an AlphaImager gel documentation system (Bio-Rad Laboratories, Inc.), and bands were quantified using ImageJ software (NIH, Bethesda, MD, USA).

Statistical analysis
--------------------

SPSS software (version 17.0; SPSS Inc., Chicago, IL, USA) was used to process data. The experimental results are expressed as the mean ± standard deviation, and were analyzed by Student\'s t-test with a two-tailed distribution. For multiple group comparisons, analysis of variance with Tukey\'s post hoc test was applied. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

Morphology of the TS NSCs
-------------------------

At day 1 in primary culture, the cells were small and round, 5-10 *μ*m in diameter, with no cell processes under a microscope. The distribution appeared scattered in cell suspension, but with excellent refraction. At day 3 in primary culture, small cell spheres arose in the liquid and grew in a clustered and floating manner. At day 5 in primary culture, spherical colonies formed by dozens of cells could be observed. With the development of time, the number and the diameter of the spherical colonies markedly increased. Following continuous passaging, at P1 and P2, greater numbers of NSCs were obtained, whose growth characteristics were similar to that of the original generation ([Fig. 1A](#f1-ijmm-41-06-3267){ref-type="fig"}).

Proliferation of NSCs cultured in vitro
---------------------------------------

The number of NSCs decreased significantly in the P0 and P1 groups (P\<0.01), while in P2, the difference in the number of NSC exhibited no statistical significance (P\>0.05) between days 3 and 5. Among all groups, the number of the cultured NSCs at day 3 in P2 was significantly fewer than that in P0 or P1 (P\<0.01), while for the cultured NSCs at day 5, there was no significant difference among P0, P1 and P2 (P\>0.05) ([Fig. 1B](#f1-ijmm-41-06-3267){ref-type="fig"}). Meanwhile, the size of the cultured NSCs was also calculated, and the comparison between days 3 and 5 of P0, P1 and P2 showed that the mean size of the NSCs (neurospheres) at day 5 was significantly larger than that at day 3 in P0, whereas the size changes between days3 and 5 in P1 and P2 exhibited no statistical significance (P\>0.05). In addition, comparison among P0, P1 and P2 groups revealed no significance (P\>0.05) ([Fig. 1C](#f1-ijmm-41-06-3267){ref-type="fig"}).

Identification and differentiation of TS NSCs
---------------------------------------------

To identify the cultured TS NSCs and evaluate the differentiation phenotype of the grafted cells *in vitro*, immunohistochemical staining of Nestin, NeuN and GFAP was performed at P2 after culture. In close approximation of our expectations, the rate of Nestin-positive expression was 99.58%, which confirmed the purity of the cultured NSCs. Almost all NSCs were NeuN-positive (97.23%), which implied that the majority of the cultured TS NSCs differentiated into neurons. The GFAP-positive rate was 46.99% in NSCs, which explained why a small quantity of NSCs differentiated into astrocytes ([Fig. 2](#f2-ijmm-41-06-3267){ref-type="fig"}).

Expression of NTFs in the cultured TS NSCs
------------------------------------------

Using the double-labeled immunofluorescence staining of BDNF CNTF, GDNF, IGF, TGF-β1 and NGF with DAPI, the expression of these NTFs expressed in the cultured TS NSCs were detected at P2 following culture. The results showed that the cultured TS NSCs exhibited positive immunoreactivity for the aforementioned NTFs. Moreover, quantitative analysis showed that the positive rates of CNTF, GDNF and IGF were 100%, and that the positive rate of TGF-β1 was 96.67%. NGF had a positive rate of 89.96%. Furthermore, BDNF was observed with a positive rate of 50%. This outcome indicated that NSCs can secrete CNTF, GDNF, IGF, TGF-β1, NGF and a small amount of BDNF ([Fig. 3](#f3-ijmm-41-06-3267){ref-type="fig"}).

BBB score
---------

The changes of hind-limb function were assessed using the BBB scores from days 1 to 16 post-hSCI. hSCI resulted in spastic paralysis on the injury side of the TSs, as well as flaccid paralysis on the other side, with a BBB score of 3 at day 1 post-injury in the four groups. Over time, the locomotor function could be partially restored. At day 7 post-injury, the hind-limb locomotor functions had recovered spontaneously to an approximate BBB score of 10. Moreover, in the chronic group, significantly greater functional recovery was observed compared with that in the chronic control group at day 16 post-injury (P\<0.05). By contrast, the acute group did not show any functional recovery compared with the acute control group ([Fig. 4](#f4-ijmm-41-06-3267){ref-type="fig"}).

Survival, migration and differentiation of the transplanted NSCs in vivo
------------------------------------------------------------------------

At day 16 post-injury in the chronic group, a large number of surviving NSCs with blue nuclei staining labeled by Hoechst 33342 could be found in the spinal cord of the NSC-transplanted TSs (near the needle passage), whereas there were no Hoechst-positive cells in the control group; the results indicated that NSCs could survive and migrate in the spinal cord around the injection site ([Fig. 5A](#f5-ijmm-41-06-3267){ref-type="fig"}). In order to detect the differentiation of NSCs in the host spinal cord, the immunohistochemical staining of specific markers was performed to recognize neurons and astrocytes, as performed *in vitro*. The implanted NSCs with blue nuclei staining were found in the host spinal cord, confirming the survival of the NSCs ([Fig. 5B and C](#f5-ijmm-41-06-3267){ref-type="fig"}). Simultaneously, positive staining of neuron marker NeuN confirmed the differentiation of NSCs into neurons ([Fig. 5B](#f5-ijmm-41-06-3267){ref-type="fig"}). In addition, a few NSCs exhibited GFAP-positive staining, a marker of astrocytes, demonstrating the differentiation of the transplanted NSCs into astrocytes ([Fig. 5C](#f5-ijmm-41-06-3267){ref-type="fig"}). The merged images revealed that in the chronic group, certain grafted cells differentiated into NeuN-positive cells (33.8±0.6%), followed by GFAP-positive astrocytes (20.3±5.1%) ([Fig. 5B-D](#f5-ijmm-41-06-3267){ref-type="fig"}).

Expression of NTFs in vivo following NSC transplantation
--------------------------------------------------------

In order to detect the mechanism of the functional recovery at day 16 post-injury in the chronic group, RT-qPCR was employed to confirm NTF gene expression *in vivo* among the sham, hSCI and NSCs transplantation groups. Compared with the mRNA of NSCs from the sham group, NGF gene expression was increased markedly in the chronic group (P\<0.05), while there was no significant difference for CNTF, BDNF ([Fig. 6](#f6-ijmm-41-06-3267){ref-type="fig"}), IGF, TGF-β1 and GDNF (data not shown) among the above three groups.

Discussion
==========

In the present study, it was demonstrated *in vitro* and *in vivo* that the NSCs from TSs possessed the potential for self-renewal, pluripotency into neurons and astrocytes, and the production of different types of NTFs, including CNTF, TGF-β1, GDNF, NGF, BDNF and IGF. Following transplantation in the chronic phase of hSCI, the BBB score revealed that the locomotor function in the hind-limbs was improved, but that there was no statistical significance in the acute-phase transplantation, when compared with the control group. To the best of our knowledge, these findings, for the first time, indicate that the transplantation of NSCs from TSs is available for neurological function improvement following hSCI, but only in the acute phase, and that the expression of multiple NTFs linked with the upregulation of NGF is probably involved in the underlying mechanism. In the experiments assessing the proliferation of NSCs from TSs, it was confirmed that the NSCs possessed the capacity to proliferate *in vitro* and *in vivo*. *In vitro*, the number of NSCs in P0 and P1 reached the growth peak in culture on day 3. The area of neurosphere formation kept increasing as well throughout the culture, which innovatively illustrated that NSCs from TSs can successfully proliferate *in vitro*. These results suggested that NSCs from TSs could be considered as an available cell source for the treatment of disease. *In vivo*, via local injections of NSCs, transplanted NSCs from TSs were verified to survive and proliferate in the hSC of other TSs, which is useful for understanding the functional repair occurring following hSCI in non-human primates.

The majority of NSC experimental models have been focused on rodents and few studies have involved the use of primates or humans due to the associated ethical issues and the lack of availability ([@b33-ijmm-41-06-3267]-[@b37-ijmm-41-06-3267]). Compared with rats, TSs exhibit biological characteristics and gross anatomy that are more similar to those of humans ([@b24-ijmm-41-06-3267],[@b38-ijmm-41-06-3267]). Furthermore, TSs have a lower economic cost and are a more convenient resource than other animals. Therefore, TSs have more advantages as translational research on NSCs than rodents.

The present study verified that NSCs from TSs could differentiate into neurons and astrocytes *in vivo* and *in vitro*, which may replace the damaged nerve cells to restore the structure of the injured spinal cord following transplantation. Over the past decades, NSCs have been reported to exhibit multi-directional differentiation to neurons and astrocytes ([@b13-ijmm-41-06-3267],[@b21-ijmm-41-06-3267],[@b36-ijmm-41-06-3267],[@b39-ijmm-41-06-3267]). However, the differentiation ability of NSCs in non-human primates, such as TSs, was previously unknown. To the best of our knowledge, the present study was the first to demonstrate the differentiation characteristics of NSCs from TSs. The present experiments therefore provided crucial evidence that NSCs can differentiate into neurons and glial cells, which assist in reconstructing neural injury.

In the present study, the BBB score exhibited no significant difference in terms of varying observation points in the acute phase group compared with those in the acute control group; this indicated that NSC implantation in the chronic phase could contribute to the recovery of nervous function in TSs, but not in the acute phase. A number of studies found that the degenerative degree of the spinal cord tissue near the spinal cord transection or contusion was reduced significantly following NSC transplantation in the chronic phase ([@b40-ijmm-41-06-3267],[@b41-ijmm-41-06-3267]), but associated mechanisms involved in the NTFs were not mentioned, let alone the non-human primate tree shrew model. Therefore, the present study obtained novel findings that NSC transplantation into TSs in the chronic phase could effectively improve nervous function, which may be linked to the secretion of NTFs in the chronic group.

The results of IHC and RT-qPCR showed that NSCs could secrete CNTF, TGF-β1, GDNF, NGF, BDNF and IGF *in vitro*, while NGF gene expression increased markedly *in vivo*. The upregulation of NGF may contribute to neuronal growth, development and functional integrity, therefore improving the BBB scores in the hSCI TSs with NSC transplantation. According to previous studies, there are two main hypotheses for the effectively promotion of neural functional recovery by NSCs: The alternative theory and the nutrition theory. Previous studies have demonstrated that NSC transplantation can differentiate into neurons and glial cells to repair the neuronal necrosis, but little evidence shows that grafted NSCs can integrate into the neural networks of the host. Therefore, whether grafted NSCs can integrate into host neural network has become important for research, as this may help to further interpret the role of NSCs transplantation in the restoration of nerve function ([@b14-ijmm-41-06-3267]-[@b17-ijmm-41-06-3267],[@b42-ijmm-41-06-3267]-[@b44-ijmm-41-06-3267]). The present results showed that the upregulated NGF expression expressed by NSCs directly or caused by NSCs indirectly could promote survival and proliferation, and ultimately improve motor function following hSCI. These results will aid in understanding the molecular mechanisms for stem cell therapy in diseases of non-human primates, which may ultimately become available to future patients in the clinic.
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![Morphology of TS NSCs cultured *in vitro*. (A) TS NSCs were observed under a microscope without dye processing on days 1, 3 and 5 of primary culture (P0), and subculture (P1 and P2). Scale bar, 100 *μ*m. (B and C) The number of NSCs in the different culture stages (P0, P1 and P2) was compared at different culture times (days 3 and 5). Data are presented as the mean ± SD (n=5). The area of NSCs in the different culture stages (P0, P1 and P2) was compared at different times (days 3 and 5). Data are presented as the mean ± SD (n=6). TS, tree shrew; NSC, neural stem cell; P, passage; d, day; SD, standard deviation.](IJMM-41-06-3267-g00){#f1-ijmm-41-06-3267}

![Identification and differentiation of the cultured TS NSCs. (A) Immunofluorescent staining of Nestin (red, left) for identifying the TS NSCs, DAPI with blue staining was shown in middle and the merge picture showed Nestin positive rate was 99.58% (right). (B and C) Immunofluorescent staining of NeuN and GFAP for confirmation of the differentiation of the cultured NSCs into neurons and astrocytes (red, left). DAPI stained the nuclei with blue florescence (middle). Merged images show the NeuN- and GFAP-positive cells, from which expression rates of 97.23 and 46.99%, respectively, were obtained (right). White arrows represent the positive cells. Scale bar, 50 *μ*m. Cells from five fields in each well were collected, and each detection *in vitro* was prepared for 6 plates (6-pore plate) of cells. (D) Representative bar graph for the rate of positive cells. TS, tree shrew; NSC, neural stem cell; DAPI, 4′,6-diamidino-2-phenylindole; GFAP, glial fibrillary acidic protein; NeuN, neuron-specific nuclear protein.](IJMM-41-06-3267-g01){#f2-ijmm-41-06-3267}

![Expression of NTFs in the NSCs of tree shrews. Immunofluorescent staining of CNTF, TGF-β1, GDNF, NGF, BDNF and IGF is shown in the left of (A-F) (red), and cell nuclei were redyed by 4′,6-diamidino-2-phenylindole (DAPI) (blue) *in vitro* (A-F, middle). The merged images show positive CNTF (B; right), GDNF (C; right) and IGF (D; right) expression, with a determined mean rate of 100%, BDNF (A, right) was 50%, NGF was 89.96% (E, right) and TGF-β1 was 96.67% (F, right). Scale bar, 50 *μ*m. White arrows represented the positive cells. Cells from five fields in each well were collected, each detection *in vitro* was prepared for six plates (six-pore plate) of cells. NTF, neurotrophic factors; NSCs, neural stem cells; CNTF, ciliary NTF; TGF-β1, transforming growth factor-β1; GDNF, glial cell line-derived NTF; NGF, nerve growth factor; BDNF, brain-derived NTF; IGF, insulin-like growth factor.](IJMM-41-06-3267-g02){#f3-ijmm-41-06-3267}

![Analysis of functional recovery measured by BBB scores following NSC transplantation. (A) The BBB scores in hSCI tree shrews treated with NSCs immediately after hSCI did not differ from those of the controls. (B) The chronic group exhibited significantly better functional recovery than the chronic control group at day 16 post-injury. Data are presented as the mean ± standard deviation (n=10). ^\*^P\<0.01 vs. control group. Arrowheads indicate the transplantation time. Chronic, NSC transplantation at day 9 post-injury; acute, NSC transplantation immediately after injury; TS, tree shrew; BBB, Basso-Beattie-Bresnahan; NSC, neural stem cell; hSCI, hemi-sectioned spinal cord injury.](IJMM-41-06-3267-g03){#f4-ijmm-41-06-3267}

![Transplanted TS NSCs survived and differentiated into neurons and glia-like cells *in vivo*. (A) NSCs labeled with Hoechst (blue fluorescence, left) survived and migrated at day 16 post-injury *in vivo*. The control exhibited no positive reactivity (right). (B) Hoechst^+^ grafted NSCs (blue florescence, middle) differentiated into NeuN^+^ neurons (green florescence, left), and GFAP^+^ astrocytes (red, left) in the chronic groups, with merged images shown in the right panels. Scale bar, (A) 100 *μ*m and (B and C) 50 *μ*m. White arrows indicate the positive cells. The images were captured 1 cm below the lesion. (D) Representative bar graph for the rate of NeuN- and GFAP-positive cells. NSC, neural stem cell; TS, tree shrew; NeuN, neuron-specific nuclear protein; GFAP, glial fibrillary acidic protein.](IJMM-41-06-3267-g04){#f5-ijmm-41-06-3267}

![Expression of NTFs *in vivo* after tree shrew NSC transplantation. (A) Analysis of CNTF mRNA expression in the spinal cord tissues caudal to the injured site (20-mm long containing the injury and injection sites) among the sham, hSCI and NSC transplantation groups in the chronic phase at day 16 post-injury. (B) Analysis of BDNF mRNA expression in the tissues aforementioned. (C) Analysis of NGF mRNA expression in the tissues aforementioned. \*P\<0.05 vs. NSC group. Data are represented as the mean ± SD (n=10). NSC, neural stem cell; hSCI, hemi-sectioned spinal cord injury; NTF, neurotrophic factor; CNTF, ciliary NTF; BDNF, brain-derived NTF; NGF, nerve growth factor.](IJMM-41-06-3267-g05){#f6-ijmm-41-06-3267}

###### 

Animals and grouping (n=50).

  Groups                 n    BBB   RT-qPCR   IF
  ---------------------- ---- ----- --------- ----
  Sham                   10   10    5         5
  Acute hSCI with NSCs   10   10    5         5
  Acute hSCI with MEM    10   10    5         5
  Chro hSCI with NSCs    10   10    5         5
  Chro hSCI with MEM     10   10    5         5

hSCI, hemi-sectioned spinal cord injury; NSCs, neural stem cells; RT-qPCR, reverse transcription-quantitative polymerase chain reaction; IF, immunofluorescence; Chro, chronic; MEM, minimal essential medium; BBB, Basso-Beattie-Bresnahan motor score.

###### 

Antibody list.

  Primary antibody                                      Company                                                   Species   Concentration   Secondary antibody   Company                                                     Species            Concentration   Cat. nos.
  ----------------------------------------------------- --------------------------------------------------------- --------- --------------- -------------------- ----------------------------------------------------------- ------------------ --------------- -------------
  IGF                                                   ZSGB-BIO[a](#tfn2-ijmm-41-06-3267){ref-type="table-fn"}   Rabbit    1:50            Cy3                  Jackson[b](#tfn3-ijmm-41-06-3267){ref-type="table-fn"}      Goat anti-rabbit   1:200           111-165-003
  BDNF                                                  ZSGB-BIO                                                  Rabbit    1:50            Cy3                  Jackson                                                     Goat anti-rabbit   1:200           111-165-003
  NGF                                                   ZSGB-BIO                                                  Rabbit    1:50            Cy3                  Jackson                                                     Goat anti-rabbit   1:200           111-165-003
  GDNF                                                  ZSGB-BIO                                                  Rabbit    1:100           Cy3                  Jackson                                                     Goat anti-rabbit   1:200           111-165-003
  TGF-β1                                                Abcam[c](#tfn4-ijmm-41-06-3267){ref-type="table-fn"}      Rabbit    1:100           Cy3                  Jackson                                                     Goat anti-rabbit   1:200           111-165-003
  CNTF                                                  Bioss[d](#tfn5-ijmm-41-06-3267){ref-type="table-fn"}      Rabbit    1:50            Cy3                  Jackson                                                     Goat anti-rabbit   1:200           111-165-003
  GFAP                                                  ZSGB-BIO                                                  Rabbit    1:50            Cy3                  Jackson                                                     Goat anti-rabbit   1:200           111-165-003
  NeuN[e](#tfn6-ijmm-41-06-3267){ref-type="table-fn"}   Bioss                                                     Rabbit    1:100           Cy3                  Jackson                                                     Goat anti-mouse    1:200           111-165-003
  NeuN[f](#tfn7-ijmm-41-06-3267){ref-type="table-fn"}   Bioss                                                     Rabbit    1:100           488                  Invitrogen[g](#tfn8-ijmm-41-06-3267){ref-type="table-fn"}   Goat anti-rabbit   1:100           A-11034
  Nestin                                                ZSGB-BIO                                                  Rabbit    1:50            Cy3                  Jackson                                                     Goat anti-rabbit   1:200           111-165-003

ZSGB-BIO; Origene Technologies, Inc., Beijing, China;

Jackson,;

Abcam, Cambridge, MA, USA;

Bioss, Woburn, MA, USA;

NeuN detection *in vitro*;

NeuN detection *in vivo*;

Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA. Cell identification, Nestin. Differentiation identification: GFAP and NeuN. NTF: IGF, BDNF, NT-3, GDNF, TGF-β1 and CNTF. NeuN, neuron-specific nuclear protein; IGF, insulin-like growth factor; BDNF, brain-derived neurotrophic factor; NGF, nerve growth factor; GDNF, glial cell line-derived neurotrophic factor; TGF-β1, transforming growth factor-β1, CNTF, ciliary neurotrophic factor; GFAP, glial fibrillary acidic protein.

###### 

Information of primer sequences.

  Gene      Upstream                       Downstream                   Annealing temperature, °C
  --------- ------------------------------ ---------------------------- ---------------------------
  CNTF      5′-AGGAAGATTCGTTCAGACCT-3′     5′-GTTCTCTTGGAGTCGCTCTG-3′   53
  TGF-β1    5′-GGCAGCTGTACATTGACTT-3′      5′-AGGGCAAGGACCTTGCTGT-3′    53
  GDNF      5′- TCTGCCTGGTGTTGCTCC-3′      5′-CCTCTGCGACCTTTCCCT-3′     52
  NGF       5′-GAAGCCCACTGGACTAAACT-3′     5′-ACAGTGATGTTGCGGGTCTG-3′   54
  BDNF      5′-GGTGTCGTAAAGTTCCACCA-3′     5′-GCCAAGTTGCCTTGTCCGT-3′    54
  IGF       5′-GATACACATCATGTCGTCTT-3′     5′-GCCTGTGGGCTTGTTGAAGT-3′   50
  β-actin   5′-GAAGATCAAGATCATTGCTCCT-3′   5′-TACTCCTGCTTGCTGATCCA-3′   52

CNTF, ciliary neurotrophic factor; TGF-β1, transforming growth factor-β1; GDNF, glial cell line-derived neurotrophic factor; NGF, nerve growth factor; BDNF, brain-derived neurotrophic factor; IGF, insulin-like growth factor.
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